These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
744 related articles for article (PubMed ID: 18448272)
1. High-dose-rate brachytherapy of a single implant with two fractions combined with external beam radiotherapy for hormone-naive prostate cancer. Sato M; Mori T; Shirai S; Kishi K; Inagaki T; Hara I Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1002-9. PubMed ID: 18448272 [TBL] [Abstract][Full Text] [Related]
2. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471 [TBL] [Abstract][Full Text] [Related]
3. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity. Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838 [TBL] [Abstract][Full Text] [Related]
4. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation. Vicini FA; Kestin LL; Martinez AA Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815 [TBL] [Abstract][Full Text] [Related]
5. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788 [TBL] [Abstract][Full Text] [Related]
6. High-dose-rate brachytherapy plus external beam radiotherapy for T1 to T3 prostate cancer: an experience in Taiwan. Chen YC; Chuang CK; Hsieh ML; Chen WC; Fan KH; Yeh CY; Lee CC; Hong JH Urology; 2007 Jul; 70(1):101-5. PubMed ID: 17656217 [TBL] [Abstract][Full Text] [Related]
7. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244 [TBL] [Abstract][Full Text] [Related]
8. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity. Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone. Fang FM; Wang YM; Wang CJ; Huang HY; Chiang PH Jpn J Clin Oncol; 2008 Jul; 38(7):474-9. PubMed ID: 18621848 [TBL] [Abstract][Full Text] [Related]
10. 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer. Martin T; Röddiger S; Kurek R; Dannenberg T; Eckart O; Kolotas C; Heyd R; Rogge B; Baltas D; Tunn U; Zamboglou N Radiother Oncol; 2004 Apr; 71(1):35-41. PubMed ID: 15066294 [TBL] [Abstract][Full Text] [Related]
11. Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report. Valero J; Cambeiro M; Galán C; Teijeira M; Romero P; Zudaire J; Moreno M; Ciérvide R; Aristu JJ; Martínez-Monge R Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):386-92. PubMed ID: 19427741 [TBL] [Abstract][Full Text] [Related]
12. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Demanes DJ; Rodriguez RR; Schour L; Brandt D; Altieri G Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1306-16. PubMed ID: 15817332 [TBL] [Abstract][Full Text] [Related]
13. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy. Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980 [TBL] [Abstract][Full Text] [Related]
14. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation. Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527 [TBL] [Abstract][Full Text] [Related]
15. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life. Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166 [TBL] [Abstract][Full Text] [Related]
16. High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer. Jo Y; Hiratsuka J; Fujii T; Takenaka A; Fujisawa M Urology; 2004 Sep; 64(3):556-60. PubMed ID: 15351592 [TBL] [Abstract][Full Text] [Related]
17. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279 [TBL] [Abstract][Full Text] [Related]
18. Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups? Galalae RM; Martinez A; Nuernberg N; Edmundson G; Gustafson G; Gonzalez J; Kimming B Strahlenther Onkol; 2006 Mar; 182(3):135-41. PubMed ID: 16520907 [TBL] [Abstract][Full Text] [Related]
19. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. Martinez A; Gonzalez J; Spencer W; Gustafson G; Kestin L; Kearney D; Vicini FA J Urol; 2003 Mar; 169(3):974-9; discussion 979-80. PubMed ID: 12576825 [TBL] [Abstract][Full Text] [Related]
20. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Lee B; Shinohara K; Weinberg V; Gottschalk AR; Pouliot J; Roach M; Hsu IC Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1106-12. PubMed ID: 17197119 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]